After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options.

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. This expansion positions Dupixent as the first targeted therapy for ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Paris: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the ...

Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA ...